These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 20940211)

  • 1. Finding studies on reboxetine: a tale of hide and seek.
    Wieseler B; McGauran N; Kaiser T
    BMJ; 2010 Oct; 341():c4942. PubMed ID: 20940211
    [No Abstract]   [Full Text] [Related]  

  • 2. Reboxetine: a norepinephrine selective reuptake pump inhibitor.
    Preskorn SH
    J Psychiatr Pract; 2004 Jan; 10(1):57-63. PubMed ID: 15334987
    [No Abstract]   [Full Text] [Related]  

  • 3. Reboxetine and treatment-refractory elderly patients with depression.
    Chue P
    Can J Psychiatry; 2000 Sep; 45(7):669. PubMed ID: 11056834
    [No Abstract]   [Full Text] [Related]  

  • 4. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Publication bias and the efficacy of antidepressants.
    Mathew SJ; Charney DS
    Am J Psychiatry; 2009 Feb; 166(2):140-5. PubMed ID: 19188290
    [No Abstract]   [Full Text] [Related]  

  • 6. Sleepwalking associated with reboxetine in a young female patient with major depression--a case report.
    Künzel HE; Schuld A; Pollmächer T
    Pharmacopsychiatry; 2004 Nov; 37(6):307-8. PubMed ID: 15551201
    [No Abstract]   [Full Text] [Related]  

  • 7. Collecting race and ethnicity data in clinical human research projects.
    Maloney DM
    Hum Res Rep; 2003 Mar; 18(3):1-2. PubMed ID: 14603942
    [No Abstract]   [Full Text] [Related]  

  • 8. Escitalopram/reboxetine combination in depressed patients with substance use disorder.
    Camarasa X; Lopez-Martinez E; Duboc A; Khazaal Y; Zullino DF
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):165-8. PubMed ID: 15610962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reboxetine in clinical practice: a review.
    Sepede G; Corbo M; Fiori F; Martinotti G
    Clin Ter; 2012 Jul; 163(4):e255-62. PubMed ID: 23007832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoxetine associated with thrombocytopenia and treatment with reboxetine: 3 cases.
    Yucel A; Yucel N; Ozcan H; Gulec M; Aydin A
    J Clin Psychopharmacol; 2015 Jun; 35(3):354-5. PubMed ID: 25822478
    [No Abstract]   [Full Text] [Related]  

  • 11. Reboxetine in depression. All the relevant data?
    Turner EH
    BMJ; 2010 Nov; 341():c6487. PubMed ID: 21081614
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study.
    Akkaya C; Sivrioglu EY; Akgoz S; Eker SS; Kirli S
    Hum Psychopharmacol; 2006 Jul; 21(5):337-45. PubMed ID: 16856215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
    Fava M; McGrath PJ; Sheu WP;
    J Clin Psychopharmacol; 2003 Aug; 23(4):365-9. PubMed ID: 12920412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode.
    Pintor L; Baillès E; Valldeoriola F; Tolosa E; Martí MJ; de Pablo J
    Gen Hosp Psychiatry; 2006; 28(1):59-64. PubMed ID: 16377367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Failure rate and "professional subjects" in clinical trials of major depressive disorder.
    Shiovitz TM; Zarrow ME; Shiovitz AM; Bystritsky AM
    J Clin Psychiatry; 2011 Sep; 72(9):1284; author reply 1284-5. PubMed ID: 21951988
    [No Abstract]   [Full Text] [Related]  

  • 16. Scientific harassment by pharmaceutical companies: time to stop.
    Hailey D
    CMAJ; 2000 Jan; 162(2):212-3. PubMed ID: 10674057
    [No Abstract]   [Full Text] [Related]  

  • 17. Commercial and non-commercial 'championing' of medications.
    Parry P
    Aust N Z J Psychiatry; 2010 Jun; 44(6):585. PubMed ID: 20482422
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug approval and drug effectiveness.
    Spielmans GI; Kirsch I
    Annu Rev Clin Psychol; 2014; 10():741-66. PubMed ID: 24329178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reboxetine addition in patients with mirtazapine-resistant depression: a case series.
    López-Muñoz F; Rubio G; Alamo C; García-García P; Pardo A
    Clin Neuropharmacol; 2006; 29(4):192-6. PubMed ID: 16855420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosing strategies for antidepressant clinical trials: a commentary.
    Robinson DS; Khan A
    J Clin Psychopharmacol; 2004 Feb; 24(1):1-3. PubMed ID: 14709939
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.